DM
TVTX icon

Deerfield Management’s Travere Therapeutics TVTX Stock Holding History

Deerfield Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-158,223
Closed -$3.79M – 134
2015
Q1 		$3.79M Buy
+158,223
New +$2.41M 0.12% 93

Other funds holding TVTX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management's TVTX Position: Q2 2015 in Review

Deerfield Management sold out of Travere Therapeutics (TVTX) in Q2 2015, closing a stake of 158,223 shares — an estimated $3.79M sold.

Deerfield Management first reported a position in TVTX in Q1 2015 and held it in 1 quarter. The position peaked at $3.79M in Q1 2015. 126 funds tracked by Wall St. Rank hold TVTX as of Q2 2015.

  • Deerfield Management reported no remaining Travere Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Deerfield Management sold 158,223 Travere Therapeutics shares in Q2 2015, an estimated $3.79M.
  • Deerfield Management first reported a position in Travere Therapeutics in Q1 2015 and held it in 1 quarter.
  • Deerfield Management's Travere Therapeutics position peaked at $3.79M in Q1 2015.
  • 126 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2015.

Based on Deerfield Management's 13F filing for Q2 2015, filed 14 Aug 2015.